Attached files
| file | filename |
|---|---|
| EX-10.22 - COMMERCIAL LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1022.htm |
| EX-10.23 - LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1023.htm |
| EX-10.18 - AMENDMENT NO. 1 TO EXCLUSIVE PATENT LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1018.htm |
| EX-10.19 - EXCLUSIVE PATENT LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1019.htm |
| EX-10.17 - EXCLUSIVE PATENT LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1017.htm |
| EX-10.24 - LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1024.htm |
| EX-10.21 - NON-EXCLUSIVE CABILLY PATENT LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1021.htm |
| EX-10.20 - AMENDMENT NO. 1 TO EXCLUSIVE PATENT LICENSE AGREEMENT - Avid Bioservices, Inc. | peregrine_8k-ex1020.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): April 14, 2010
PEREGRINE PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-17085
|
95-3698422
|
||
|
(State
of other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Company
Identification
No.)
|
||
|
14282
Franklin Avenue, Tustin, California 92780
|
||||
|
(Address
of Principal Executive Offices)
|
||||
|
Registrant’s
telephone number, including area code: (714)
508-6000
|
||||
|
Not
Applicable
|
||||
|
(Former
name or former address, if changed since last
report)
|
||||
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425).
|
|
o
|
Soliciting
material pursuant to Rule 14A-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other Events.
Peregrine
Pharmaceuticals, Inc. (the “Company”) is filing this Current Report on Form 8-K
solely for the purpose of filing the attached Exhibits in response to a comment
letter dated March 8, 2010, received from the staff of the Securities and
Exchange Commission (“SEC”) regarding its review of the Company’s Form 10-K for
the fiscal year ended April 30, 2009. Certain information contained
in the attached Exhibits has been redacted pursuant to the Company’s requests
for confidential treatment, which requests have been submitted to the SEC on the
date of this filing.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
10.17
|
Exclusive
Patent License Agreement between The University of Texas System and
Peregrine Pharmaceuticals, Inc. effective as of August 18, 2005
*
|
|
|
10.18
|
Amendment
No. 1 to Exclusive Patent License Agreement between The University of
Texas System and Peregrine Pharmaceuticals, Inc. dated June 1, 2009
*
|
|
|
10.19
|
Exclusive
Patent License Agreement between The University of Texas System and
Peregrine Pharmaceuticals, Inc. effective as of August 1, 2001
*
|
|
|
10.20
|
Amendment
No. 1 to Exclusive Patent License agreement between The University of
Texas System and Peregrine Pharmaceuticals, Inc. dated June 1, 2009
*
|
|
|
10.21
|
Non-Exclusive
Cabilly Patent License Agreement between Genentech, Inc. and Peregrine
Pharmaceuticals, Inc. effective as of November 5, 2003
*
|
|
|
10.22
|
Commercial
License Agreement between Avanir Pharmaceuticals, Inc. and Peregrine
Pharmaceuticals, Inc. dated December 1, 2003 *
|
|
|
10.23
|
License
Agreement between Lonza Biologics PLC and Peregrine Pharmaceuticals, Inc.
dated July 1, 1998 *
|
|
|
10.24
|
License
Agreement between Lonza Biologics PLC and Peregrine Pharmaceuticals, Inc.
dated March 1, 2005 *
|
* Portions
of the attached exhibits have been redacted in connection with the Company’s
request for confidential treatment which has been submitted to the Securities
and Exchange Commission in connection with the filing of this Current
Report.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PEREGRINE
PHARMACEUTICALS, INC.
|
|||
|
Date:
April 14, 2010
|
By:
|
/s/ Paul J. Lytle | |
| Paul J. Lytle | |||
|
Chief
Financial Officer and
|
|||
|
Corporate
Secretary
|
|||
Exhibit
Index
|
Exhibit No.
|
|
Description
|
|
10.17
|
Exclusive
Patent License Agreement between The University of Texas System and
Peregrine Pharmaceuticals, Inc. effective as of August 18, 2005
*
|
|
|
10.18
|
Amendment
No. 1 to Exclusive Patent License Agreement between The University of
Texas System and Peregrine Pharmaceuticals, Inc. dated June 1, 2009
*
|
|
|
10.19
|
Exclusive
Patent License Agreement between The University of Texas System and
Peregrine Pharmaceuticals, Inc. effective as of August 1, 2001
*
|
|
|
10.20
|
Amendment
No. 1 to Exclusive Patent License agreement between The University of
Texas System and Peregrine Pharmaceuticals, Inc. dated June 1, 2009
*
|
|
|
10.21
|
Non-Exclusive
Cabilly Patent License Agreement between Genentech, Inc. and Peregrine
Pharmaceuticals, Inc. effective as of November 5, 2003
*
|
|
|
10.22
|
Commercial
License Agreement between Avanir Pharmaceuticals, Inc. and Peregrine
Pharmaceuticals, Inc. dated December 1, 2003 *
|
|
|
10.23
|
License
Agreement between Lonza Biologics PLC and Peregrine Pharmaceuticals, Inc.
dated July 1, 1998 *
|
|
|
10.24
|
License
Agreement between Lonza Biologics PLC and Peregrine Pharmaceuticals, Inc.
dated March 1, 2005 *
|
* Portions
of the attached exhibits have been redacted in connection with the Company’s
request for confidential treatment which has been submitted to the Securities
and Exchange Commission in connection with the filing of this Current
Report.